Yingbing Wang

RLJ has served as a consultant for GE healthcare and Dayglen LLC. He has received travel support from the SNMMI, the EANM, and the Alzheimer s Association. DNSM received grant support from NIH. He serves on a data monitoring committee for Eli Lilly and Company. He received honoraria for grant review from the Alzheimer s Drug Discovery Foundation and non-monetary support from the SNMMI and the Alzheimer s Association. He also served on a council for the Alzheimer s Association.

OPPORTUNITY TO ELEVATE CARE IN AN ERA OF DISEASE-MODIFYING THERAPY The advent of Aβ-targeting therapies has created a need for more reliable imaging approaches that not only establish eligibility for treatment but also support monitoring of therapeutic response and long-term management. Visual reads have variability across raters (5%–15%), especially near the positivity threshold or in cases with atypical tracer distribution (e.g., focal uptake or technical artifacts).

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.